Karyopharm Therapeutics (KPTI) PT Lowered to $22 at Barclays
Barclays analyst Peter Lawson lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $26.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Infosys Ltd. (INFO:IN) (INFY) PT Raised to INR2,000 at CLSA
- Nickel Mines Ltd (NIC:AU) PT Lowered to AUD1.10 at Macquarie
- Sigma Healthcare Ltd. (SIG:AU) PT Lowered to AUD0.70 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!